share_log

Goldman Sachs Maintains Sell on Seres Therapeutics, Lowers Price Target to $1.25

Benzinga ·  Nov 3, 2023 10:58

Goldman Sachs analyst Chris Shibutani maintains Seres Therapeutics (NASDAQ:MCRB) with a Sell and lowers the price target from $4 to $1.25.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment